ClinicalTrials.gg
CompletedNCT02342184Updated Feb 4, 2016

Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome

A Phase 3 interventional study of GB-0998 in Guillain-Barré Syndrome, sponsored by Japan Blood Products Organization. Completed at 1 site in Japan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2016-02-04.

Sponsored by Japan Blood Products Organization · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Study summary

This study will carry out to assess the efficacy of GB-0998 (intravenous immunoglobulin;400mg/kg/day for five days) in the treatment of the Guillain-Barré Syndrome based on the changes in Hughes Functional Grade (FG) as primary endpoint, and in addition, to assess the safety of GB-0998.

02

Conditions studied

  • Guillain-Barré Syndrome
03

In context

Guillain-Barre Syndrome

98 studies on the registry are indexed under Guillain-Barre Syndrome; 30 are open to participants now.

This study's enrollment of 21 is below the median of 50 across 44 interventional studies indexed under Guillain-Barre Syndrome.

Browse Guillain-Barre Syndrome studies →

Lead sponsor

Japan Blood Products Organization is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In principle, patients are able to receive the treatment within 2 weeks (with limits of 4 weeks) from the start of symptoms.
  2. Patients with predominant motor neuropathy and FG is grade 4 or grade 5 (if symptoms is progressive, patients with FG is grade 3 involve in this study).
  3. Patients with plasmapheresis, and immune globulin therapy is no operation for this onset.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have the anamnesis of shock or to GB-0998.
  2. Patients who have been diagnosed as hereditary fructose intolerance.
  3. Patients who have impaired peripheral neuropathy except Guillain-Barré syndrome.
  4. Patients with history of volatile organic solvent abuse, abnormal porphyrin metabolism, history of pharynx or cutaneous diphtheria, plumbism, poliomyelitis, botulism, hysterical paralysis, toxic neuropathy.
  5. Patients who have received treatment of malignant tumors.
  6. Patients who were administered immunoglobulin within 8 weeks before .
  7. Patients who have been diagnosed IgA deficiency in their past history.
  8. Patients with severe renal disorder or decreased cardiac function.
  9. Patients who have the anamnesis of cerebro- or cardiovascular disorders, or symptom of these diseases.
  10. Patients with high risk of thromboembolism.
  11. Pregnant, lactating, and probably pregnant patients.
  12. Patients who were administered other drug within 12 weeks before consent.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    GB-0998

    Drug: GB-0998

Interventions

  • Also known as: Venoglobulin-IH

06

What researchers measure

Primary outcomes

  1. Proportion of patients with more than 1 grade improvement in Hughes Functional Grade (FG)

    Time frame: 4 weeks

Secondary outcomes

  1. days required for 1 grade improvement of FG

    Time frame: 1,2,3,4,6,8,12 weeks

  2. days required for 2 grade improvement of FG

    Time frame: 1,2,3,4,6,8,12 weeks

  3. changes in FG

    Time frame: 1,2,3,4,6,8,12 weeks

  4. proportion of patients with more than 1 grade improvement in the Arm Grade (AG) relative to baseline

    Time frame: 4weeks

  5. days required for 1 grade improvement of the AG

    Time frame: 1,2,3,4,6,8,12 weeks

  6. days required for 2 grade improvement of the AG

    Time frame: 1,2,3,4,6,8,12 weeks

  7. changes in AG

    Time frame: 1,2,3,4,6,8,12 weeks

  8. changes in grip strength

    Time frame: 1,2,4,8,12 weeks

  9. changes in manual muscle testing (MMT)

    Time frame: 1,2,4,8,12 weeks

  10. changes in activity of daily living (ADL)

    Time frame: 1,2,4,8,12 weeks

  11. changes in motor nerve conduction velocity

    Time frame: 4,12 weeks

  12. changes in FG on rescue treatment

    Time frame: 1,2,3,4,6,8,12 weeks

07

Study locations

1 site
  • Department of Neurology, Saitama Medical Center, Saitama Medical University
    Kawagoe, Saitama, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2014
First posted
Jan 19, 2015
Start
Aug 2014
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Last update
Feb 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02342184
Lead sponsor
Japan Blood Products Organization
Responsible party
Sponsor
First posted
Jan 19, 2015
Start date
Aug 2014
Primary completion
Sep 2015
Completion
Sep 2015
Last update
Feb 4, 2016

Study contacts

Kyoichi Nomura
study chair · Department of Neurology, Saitama Medical Center, Saitama Medical University, Saitama, Japan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GB-0998

Start the discussion